Immunocore’s (IMCR) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Immunocore (NASDAQ:IMCR) in a research note published on Thursday morning,Benzinga reports. The firm currently has a $71.00 target price on the stock.

Several other research analysts have also weighed in on IMCR. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research report on Monday, January 27th. Morgan Stanley restated an “equal weight” rating and issued a $35.00 price objective (down previously from $74.00) on shares of Immunocore in a report on Friday, December 13th. Finally, Mizuho lowered shares of Immunocore from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Trading Down 3.9 %

Immunocore stock opened at $29.58 on Thursday. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. Immunocore has a 12 month low of $27.69 and a 12 month high of $72.05. The company’s fifty day simple moving average is $30.06 and its 200-day simple moving average is $31.95. The stock has a market cap of $1.48 billion, a P/E ratio of -31.14 and a beta of 0.77.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Primecap Management Co. CA increased its stake in shares of Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after purchasing an additional 520,950 shares during the period. State Street Corp increased its position in Immunocore by 63.9% in the 3rd quarter. State Street Corp now owns 76,671 shares of the company’s stock worth $2,387,000 after buying an additional 29,897 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Immunocore by 25.0% during the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after buying an additional 109,206 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of Immunocore by 125.4% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock valued at $1,463,000 after acquiring an additional 27,598 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Immunocore by 7,437.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company’s stock worth $2,872,000 after acquiring an additional 91,033 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.